vs
Side-by-side financial comparison of Vanda Pharmaceuticals Inc. (VNDA) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $57.2M, roughly 1.2× Vanda Pharmaceuticals Inc.). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -246.8%, a 197.7% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 7.6%). Vanda Pharmaceuticals Inc. produced more free cash flow last quarter ($-29.5M vs $-84.7M).
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
VNDA vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.2M | $70.6M |
| Net Profit | $-141.2M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | -70.5% | -56.7% |
| Net Margin | -246.8% | -49.0% |
| Revenue YoY | 7.6% | 81958.1% |
| Net Profit YoY | -2774.3% | 54.9% |
| EPS (diluted) | $-2.40 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.2M | — | ||
| Q3 25 | $56.3M | $70.6M | ||
| Q2 25 | $52.6M | — | ||
| Q1 25 | $50.0M | — | ||
| Q4 24 | $53.2M | — | ||
| Q3 24 | $47.7M | — | ||
| Q2 24 | $50.5M | — | ||
| Q1 24 | $47.5M | — |
| Q4 25 | $-141.2M | — | ||
| Q3 25 | $-22.6M | $-34.6M | ||
| Q2 25 | $-27.2M | — | ||
| Q1 25 | $-29.5M | — | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-5.3M | — | ||
| Q2 24 | $-4.5M | — | ||
| Q1 24 | $-4.1M | — |
| Q4 25 | -70.5% | — | ||
| Q3 25 | -55.6% | -56.7% | ||
| Q2 25 | -73.2% | — | ||
| Q1 25 | -82.0% | — | ||
| Q4 24 | -19.3% | — | ||
| Q3 24 | -23.1% | — | ||
| Q2 24 | -20.1% | — | ||
| Q1 24 | -19.5% | — |
| Q4 25 | -246.8% | — | ||
| Q3 25 | -40.1% | -49.0% | ||
| Q2 25 | -51.7% | — | ||
| Q1 25 | -58.9% | — | ||
| Q4 24 | -9.2% | — | ||
| Q3 24 | -11.2% | — | ||
| Q2 24 | -9.0% | — | ||
| Q1 24 | -8.7% | — |
| Q4 25 | $-2.40 | — | ||
| Q3 25 | $-0.38 | — | ||
| Q2 25 | $-0.46 | — | ||
| Q1 25 | $-0.50 | — | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $-0.09 | — | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.9M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $327.2M | $503.0M |
| Total Assets | $488.9M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.9M | — | ||
| Q3 25 | $70.0M | $490.9M | ||
| Q2 25 | $81.0M | — | ||
| Q1 25 | $111.8M | — | ||
| Q4 24 | $102.3M | — | ||
| Q3 24 | $100.5M | — | ||
| Q2 24 | $103.0M | — | ||
| Q1 24 | $125.2M | — |
| Q4 25 | $327.2M | — | ||
| Q3 25 | $466.0M | $503.0M | ||
| Q2 25 | $486.3M | — | ||
| Q1 25 | $511.4M | — | ||
| Q4 24 | $538.5M | — | ||
| Q3 24 | $541.2M | — | ||
| Q2 24 | $542.5M | — | ||
| Q1 24 | $544.0M | — |
| Q4 25 | $488.9M | — | ||
| Q3 25 | $601.1M | $577.1M | ||
| Q2 25 | $624.7M | — | ||
| Q1 25 | $631.9M | — | ||
| Q4 24 | $656.2M | — | ||
| Q3 24 | $645.1M | — | ||
| Q2 24 | $651.4M | — | ||
| Q1 24 | $652.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-29.4M | $-84.6M |
| Free Cash FlowOCF − Capex | $-29.5M | $-84.7M |
| FCF MarginFCF / Revenue | -51.6% | -120.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-110.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-29.4M | — | ||
| Q3 25 | $-31.6M | $-84.6M | ||
| Q2 25 | $-15.3M | — | ||
| Q1 25 | $-33.1M | — | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $-14.6M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $7.6M | — |
| Q4 25 | $-29.5M | — | ||
| Q3 25 | $-31.8M | $-84.7M | ||
| Q2 25 | $-15.6M | — | ||
| Q1 25 | $-33.6M | — | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-14.7M | — | ||
| Q2 24 | $-7.0M | — | ||
| Q1 24 | $7.6M | — |
| Q4 25 | -51.6% | — | ||
| Q3 25 | -56.5% | -120.1% | ||
| Q2 25 | -29.6% | — | ||
| Q1 25 | -67.1% | — | ||
| Q4 24 | -3.8% | — | ||
| Q3 24 | -30.9% | — | ||
| Q2 24 | -13.9% | — | ||
| Q1 24 | 15.9% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.3% | 0.2% | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
VRDN
Segment breakdown not available.
